E

Euroapi SAS
PAR:EAPI

Watchlist Manager
Euroapi SAS
PAR:EAPI
Watchlist
Price: 2.966 EUR -2.11% Market Closed
Market Cap: 283.5m EUR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one EAPI stock under the Base Case scenario is 7.509 EUR. Compared to the current market price of 2.966 EUR, Euroapi SAS is Undervalued by 61%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

EAPI Relative Value
Base Case
7.509 EUR
Undervaluation 61%
Relative Value
Price
E
Worst Case
Base Case
Best Case

Valuation Multiples

0.3
P/S
P/S
Price to Sales
0.3
vs History
58
vs Industry
88
Median 3Y
0.4
Median 5Y
0.4
Industry
2.5
Forward
0.3
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
37
Median 3Y
-2.1
Median 5Y
-2.1
Industry
21.1
Forward
-14.5
More Details
2.3
P/OCF
P/OCF
Price to OCF
2.3
vs History
64
vs Industry
52
Median 3Y
3.4
Median 5Y
3.4
Industry
16.2
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
25
Median 3Y
-7.6
Median 5Y
-7.6
Industry
23.7
More Details
0.3
P/B
P/B
Price to Book Value
0.3
vs History
76
vs Industry
79
Median 3Y
0.4
Median 5Y
0.4
Industry
2.1
More Details
0.3
EV/S
EV/S
Enterprise Value to Sales
0.3
vs History
66
vs Industry
89
Median 3Y
0.6
Median 5Y
0.6
Industry
2.6
Forward
0.3
More Details
1.9
EV/GP
EV/GP
Enterprise Value to Gross Profit
1.9
vs History
66
vs Industry
73
Median 3Y
3.3
Median 5Y
3.3
Industry
5.1
More Details
4
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
4
vs History
35
vs Industry
49
Median 3Y
2.5
Median 5Y
2.5
Industry
12.4
Forward
3.8
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
3
Median 3Y
40.1
Median 5Y
40.1
Industry
15.7
Forward
-5.5
More Details
2.2
EV/OCF
EV/OCF
Enterprise Value to OCF
2.2
vs History
66
vs Industry
52
Median 3Y
5
Median 5Y
5
Industry
14.4
More Details
18.3
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
18.3
vs History
5
vs Industry
25
Median 3Y
-8.5
Median 5Y
-8.5
Industry
17.1
More Details
0.2
EV/IC
EV/IC
Enterprise Value to IC
0.2
vs History
82
vs Industry
82
Median 3Y
0.4
Median 5Y
0.4
Industry
1.8
More Details

Multiples Across Competitors

EAPI Competitors Multiples
Euroapi SAS Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
FR
Euroapi SAS
PAR:EAPI
282.4m EUR 0.3 -2.2 4 -32.1
US
Eli Lilly and Co
NYSE:LLY
732.8B USD 15 66 35.5 38.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
361.5B USD 4 16.6 12.1 15.9
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.6 19.1 13.2 15.1
CH
Roche Holding AG
SIX:ROG
206.7B CHF 3.4 25 9.4 11
CH
Novartis AG
SIX:NOVN
186.1B CHF 4.3 17.7 10.4 14
UK
AstraZeneca PLC
LSE:AZN
161.2B GBP 3.9 27.9 130.6 197
US
Merck & Co Inc
NYSE:MRK
199.3B USD 3.1 11.4 8.5 10.3
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
136B USD 2.2 17.2 7.4 10.5
P/E Multiple
Earnings Growth PEG
FR
E
Euroapi SAS
PAR:EAPI
Average P/E: 25.1
Negative Multiple: -2.2 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
66
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
16.6
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.1
18%
1.1
CH
Roche Holding AG
SIX:ROG
25
32%
0.8
CH
Novartis AG
SIX:NOVN
17.7
17%
1
UK
AstraZeneca PLC
LSE:AZN
27.9
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.4
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
17.2
30%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
FR
E
Euroapi SAS
PAR:EAPI
Average EV/EBITDA: 394.4
4
22%
0.2
US
Eli Lilly and Co
NYSE:LLY
35.5
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.1
7%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
13.2
13%
1
CH
Roche Holding AG
SIX:ROG
9.4
5%
1.9
CH
Novartis AG
SIX:NOVN
10.4
5%
2.1
UK
AstraZeneca PLC
LSE:AZN
130.6
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.5
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
2%
3.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
FR
E
Euroapi SAS
PAR:EAPI
Average EV/EBIT: 1 867
Negative Multiple: -32.1 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.7
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
15.9
13%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
15.1
14%
1.1
CH
Roche Holding AG
SIX:ROG
11
6%
1.8
CH
Novartis AG
SIX:NOVN
14
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
197
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.3
11%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.5
10%
1

See Also

Summary
EAPI intrinsic value, competitors valuation, and company profile.
DCF Valuation
EAPI stock valuation using Discount Cash Flow valuation method.
Relative Valuation
EAPI stock valuation using valuation multiples.
Wall Street Estimates
EAPI price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
EAPI stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 263,300+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.